Can Smoking Contribute to This Liver Picture?
Yes, smoking directly contributes to both elevated liver stiffness and accelerated fibrosis progression in patients with steatotic liver disease and cirrhosis, and should be considered a significant modifiable risk factor in this clinical presentation. 1, 2
Direct Impact on Liver Stiffness and Fibrosis
Smoking is independently associated with increased liver stiffness measurements in patients with fatty liver disease:
In patients with NAFLD/MASLD, smokers demonstrate significantly higher liver stiffness values (10.12 ± 10.38 kPa) compared to nonsmokers (7.26 ± 6.42 kPa, p=0.013). 3 This magnitude of difference is clinically meaningful in your patient with LS of 15.5 kPa.
Smoking is an independent risk factor for liver fibrosis (OR = 1.294, p=0.015) after adjusting for age, weight, AST levels, and platelet count. 3 The smoking index (pack-years) shows a dose-dependent relationship with fibrosis severity.
For every pack-year increase in smoking intensity, there is a 3.2 times higher likelihood of advanced fibrosis (95% CI: 2.018-6.294). 4 This demonstrates a clear dose-response relationship.
Association with Steatosis
Smoking contributes to hepatic steatosis through multiple mechanisms:
Heavy smoking is independently associated with steatosis in chronic hepatitis C patients (along with high GGT values and necroinflammation), and this steatosis appears to be the mechanistic link between smoking and fibrosis progression. 5
Current guidelines from the British Association for the Study of the Liver emphasize that cigarette smoking is associated with progressive fibrosis and should be documented in all patients with suspected NAFLD. 1
Your patient's CAP of 286 dB/m indicates moderate steatosis, and smoking likely contributes to both the steatosis burden and its progression to fibrosis.
Pathophysiological Mechanisms
Smoking affects the liver through three distinct pathways:
Toxic effects (both direct and indirect), immunologic mechanisms, and oncogenic signals. 6 These pathways involve oxidative stress and activation of oncogenic signaling cascades. 2
The combination of smoking with metabolic risk factors creates synergistic effects on liver disease progression, particularly in the context of central obesity and metabolic dysfunction. 1
Clinical Implications for Cirrhotic Patients
In patients who have already progressed to cirrhosis (as your patient appears to have based on the LS of 15.5 kPa):
Smoking is associated with increased risk of hepatocellular carcinoma independent of etiology, with pooled OR of 1.55 (95% CI: 1.46-1.65) in current smokers. 1
Smoking promotes cardiovascular disease and extrahepatic cancers in patients with steatohepatitis, which becomes particularly relevant given the competing mortality risks in cirrhotic patients. 2
All alcohol consumption should be stopped completely and permanently in individuals with advanced fibrosis or cirrhosis, 1 and the same aggressive approach should be applied to smoking cessation.
Risk Stratification Context
Your patient's liver stiffness of 15.5 kPa places them in a high-risk category:
Baseline LS ≥16.6 kPa predicts progression to cirrhosis in patients with bridging fibrosis (adjusted HR 3.99; 95% CI 2.66-5.98). 7 Your patient is approaching this threshold.
Among smokers with NAFLD, priority screening and timely intervention should be provided if they are at risk of liver fibrosis. 3
Critical Caveat
A detailed smoking history including pack-years, current smoking status, and even passive smoking exposure should be documented, 1 as passive smoking years are also independently associated with advanced fibrosis. 4 This quantification is essential for risk stratification and counseling.
Actionable Recommendation
Smoking cessation must be prioritized as it could improve rates of fibrosis regression and reduce the risk of hepatocellular carcinoma and hepatic decompensation. 2 Referral to specialized smoking cessation units should be considered, as this represents a modifiable risk factor that directly impacts both hepatic and extrahepatic outcomes in this cirrhotic patient. 2